Being more realistic about the public health impact of genomic medicine

PLoS Medicine

Volumn 7, Issue 10, 2010, Pages

  Hall, Wayne D ^a,b   Mathews, Rebecca ^a   Morley, Katherine I ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEHAVIOR CHANGE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROL STRATEGY; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMIC MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROMOTION; HUMAN; HUMAN GENOME PROJECT; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVENTIVE MEDICINE; PROSTATE CANCER; PUBLIC HEALTH; RISK ASSESSMENT; SMOKING CESSATION;

COST-BENEFIT ANALYSIS; ECONOMICS, MEDICAL; GENOME-WIDE ASSOCIATION STUDY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MEDICINE; METAGENOMICS; PUBLIC HEALTH; SOCIAL CHANGE;

EID: 78149392286     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000347     Document Type: Article

References (52)

1. Collins FS (1999) Shattuck lecture-medical and societal consequences of the Human Genome Project. N Engl J Med 341: 28-37.
2. van Ommen GJ, Bakker E, den Dunnen JT (1999) The human genome project and the future of diagnostics, treatment, and prevention. Lancet 354 Suppl 1: SI5-10.
3. Donnelly P (2008) Progress and challenges in genome-wide association studies in humans. Nature 456: 728-31.
4. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U SA 106: 9362-7.
5. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118: 1590-605.
6. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. (2009) Finding the missing heritability of complex diseases. Nature 461: 747-53.
7. Gulcher J, Stefansson K (2010) Genetic risk information for common diseases may indeed be already useful for prevention and early detection. Eur J Clin Invest 40: 56-63.
8. Khoury MJ (2003) Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 5: 261-268.
9. Khoury MJ, Yang Q, Gwinn M, Little J, Flanders WD (2004) An epidemiological assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med 6: 38-47.
10. Kraft P, Hunter DJ (2009) Genetic risk prediction-are we there yet? N Engl J Med 360: 1701-3.
11. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, et al. (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31: 33-6.
12. Visscher PM (2008) Sizing up human height variation. Nat Genet 40: 489-490.
13. Clayton DG (2009) Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet 5: e1000540. doi:10.1371/ journal.pgen.1000540.
14. Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, et al. (2006) Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med 8: 395-400.
15. Wray NR, Goddard ME, Visscher PM (2007) Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 17: 1520-8.
16. Wray NR, Yang J, Goddard ME, Visscher PM (2010) The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet. 6:e1000864. doi:10.1371/journal. pgen.1000864.
17. Janssens AC, van Duijn CM (2009) Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 1: 20.
18. Lango H, Palmer CN, Morris AD, Zeggini E, Hattersley AT, et al. (2008) Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 57: 3129-35.
19. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, et al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358: 1240-1249.
20. Van der Net JB, Janssens ACJW, Sijbrands EJG, Steyerberg EW (2009) Value of genetic profiling for the prediction of coronary heart disease. Am Heart J 158: 105-110.
21. Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358: 2796-803.
22. Visscher PM, Hill WG, Wray NR (2008) Heritability in the genomics era-concepts and misconceptions. Nat Rev Genet 9: 255-66.
23. Evans JP, Skrzynia C, Burke W (2001) The complexities of predictive genetic testing. BMJ 322: 1052-6.
24. Khoury MJ, McCabe LL, McCabe ER (2003) Population screening in the age of genomic medicine. N Engl J Med 348: 50-8.
25. Rose G (1992) The strategy of preventive medicine. Oxford: Oxford University Press.
26. Haga SB, Khoury MJ, Burke W (2003) Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat Genet 34: 347-50.
27. Ransohoff DF, Khoury MJ (2010) Personal genomics: information can be harmful. Eur J Clin Invest 40: 64-8.
28. Fiorentino M, Capizzi E, Loda M (2010) Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am 37: 131-41.
29. Barratt AL, Stockler MR (2009) Screening for prostate cancer: explaining new trial results and their implications to patients. Med J Aust 191: 226-9.
30. Hunter DJ, Khoury MJ, Drazen JM (2008) Letting the genome out of the bottle-will we get our wish? N Engl J Med 358: 105-7.
31. Peto J (2001) Cancer epidemiology in the last century and the next decade. Nature 411: 390-295.
32. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, et al. (2009) Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 361: 245-54.
33. Cameron LD, Sherman KA, Marteau TM, Brown PM (2009) Impact of genetic risk information and type of disease on perceived risk, anticipated affect, and expected consequences of genetic tests. Health Psychol 28: 307-16.
34. McBride CM, Bowen D, Brody LC, Condit CM, Croyle RT, et al. (2010) Future health applications of genomics: priorities for communication, behavioral, and social sciences research. Am J Prev Med 38: 556-65.
35. Senior V, Marteau TM, Weinman J (2000) Impact of genetic testing on causal models of heart disease and arthritis: an analogue study. Psychol Health 14: 1077-1088.
36. Wright AJ, Weinman J, Marteau TM (2003) The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tob Control 12: 227-30.
37. Marteau TM, Weinman J (2006) Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med 62: 1360-1368.
38. Chapman S, MacKenzie R (2010) The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 7: e1000216. doi:10.1371/journal.pmed.1000216.
39. McBride CM, Bepler G, Lipkus IM, Lyna P, Samsa G, et al. (2002) Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev 11: 521-528.
40. Sanderson SC, Humphries SE, Hubbart C (2008) Psychological and behavioural impact of genetic testing smokers for lung cancer risk: a phase II exploratory trial. J Health Psychol 13: 481-494.
41. Watson M, Foster C, Eeles R, Eccles D, Ashley S, et al. (2004) Psychosocial impact of breast/ ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer 91: 1787-1794.
42. White V, Hill D, Siahpush M, Bobevski I, (2003) How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tob Control 12 (Suppl 2_: ii67-74.
43. Pierce JP, Gilpin EA, Emery SL, White MM, Rosbrook B, et al. (1998) Has the California tobacco control program reduced smoking? JAMA 280: 893-899.
44. Hall WD, Madden P, Lynskey M (2002) The genetics of tobacco use: methods, findings and policy implications. Tob Control 11: 119-124.
45. Chaloupka FJ (2010) Beyond tax: the need for research on alcohol pricing policies. Addiction 105: 397-8.
46. Krueger H, Williams D, Kaminsky B, McLean D (2007) The health impact of smoking and obesity and what to do about it. Toronto: University of Toronto Press.
47. Hall WD, Gartner CE, Carter A (2008) The genetics of nicotine addiction liability: ethical and social policy implications. Addiction 103: 350-359.
48. Gundle KR, Dingel MJ, Koenig BA, (2010) 'To prove this is the industry's best hope': big tobacco's support of research on the genetics of nicotine addiction. Addiction 105: 974-983.
49. Hall WD (2005) British drinking: a suitable case for treatment? BMJ 331: 527-528.
50. Babor T, Miller P, Edwards G (2010) Vested interests, addiction research and public policy. Addiction 105: 4-5.
51. Vrecko S (2008) Capital ventures into biology: biosocial dynamics in the industry and science of gambling. Econ Soc 37: 50-67.
52. Davey Smith G, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, et al. (2005) Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 366: 1484-98.